

SEP, THE PAN-EUROPEAN SPECIALTY UROLOGY COMPANY, ACQUIRES MITEM®

5 October 2010, London: Speciality European Pharma Limited (SEP), the pan-European urology-focused specialty pharmaceutical company, is pleased to announce its acquisition of the product Mitem® from Curasan AG. Mitem is currently sold in Germany. SEP takes over German distribution rights and plans to introduce the product into other European markets once Marketing Authorisations are granted.

Mitem is an injectable mitomycin product used either on its own or in combination with other therapies in the treatment of a range of cancers. Most notably Mitem is given intravesically (into the bladder) for the treatment of bladder cancer.

Commenting on the acquisition, Geoff McMillan, Chief Executive Officer of SEP, said:

“This acquisition further enhances SEP’s product offerings to the urologist and is another milestone in the Company’s development as a pan-European urology company. It is the Company’s fourth specialist urology product, the others being Plenaxis® for the treatment of prostate cancer and Regurin® and Regurin® XL each for the treatment of overactive bladder.”

About Mitem

Mitem is a powdered form of mitomycin, a cytotoxic medicine used in the treatment of a variety of cancers, including bladder cancer. Mitomycin products have been on the market for many years, and in Germany, the largest European market for mitomycin products, they represent the standard treatment for patients with low risk bladder cancer. Intravesical therapy with Mitem is frequently used as adjuvant treatment in patients with superficial bladder cancer. Compared with surgery alone, surgery plus intravesical mitomycin has been shown to cause tumour regression and to reduce the rate of short-term tumour recurrence.

About Speciality European Pharma

Founded in April 2006, SEP is a privately owned speciality pharmaceutical company. Its mission is to become the leading urologist-focused specialty pharmaceutical business in Europe.

SEP owns worldwide rights to Plenaxis®, the world’s first approved GnRH blocker for the treatment of prostate cancer. Plenaxis gives a rapid and sustained decline in testosterone levels, which gives quick and sustained control of prostate cancer and its symptoms. Plenaxis was launched in Germany in February 2008.

SEP has distribution rights in the UK and the Republic of Ireland for two products, Regurin® and Regurin® XL, respectively twice daily and once daily treatments for overactive bladder.

SEP has distribution rights in France and Italy for Haemopressin®, a product for the treatment of bleeding oesophageal varices. This product is delivered to clinicians in a hospital setting.

SEP has established its own commercial operations in the UK, Germany, France and Italy and will market its products in other regions and territories through relationships with expert partners.